Markets
INO

Inovio, Beijing Advaccine To Advance Development Of Vaccine Against Coronavirus

(RTTNews) - Inovio Pharmaceuticals Inc. (INO) said that it has collaborated with Beijing Advaccine Biotechnology Co. to advance the development of the company's vaccine against new coronavirus in china.

The coronavirus has killed numerous people and infected thousands more in China to date.

Inovio plans to rapidly develop vaccine INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing.

Inovio aims to use Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U.S.

Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INO

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More